EyePoint Pharmaceuticals Inc’s filing revealed that its Director ANTHONY P. ADAMIS acquired Company’s shares for reported $0.67 million on Oct 23 ’24. In the deal valued at $10.04 per share,67,100 shares were bought.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, David R. Guyer bought 36,975 shares, generating $329,817 in total proceeds.
Before that, DICICCO WENDY F bought 2,567 shares. EyePoint Pharmaceuticals Inc shares valued at $19,997 were divested by the Director at a price of $7.79 per share. As a result of the transaction, DICICCO WENDY F now holds 9,967 shares, worth roughly $0.11 million.
Scotiabank initiated its EyePoint Pharmaceuticals Inc [EYPT] rating to a Sector outperform in a research note published recently. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in late August with a ‘”a Buy”‘ rating. JP Morgan began covering EYPT with “an Overweight” recommendation on January 22, 2024. Mizuho started covering the stock on November 02, 2023. It rated EYPT as “a Buy”.
Price Performance Review of EYPT
On Tuesday, EyePoint Pharmaceuticals Inc [NASDAQ:EYPT] saw its stock fall -7.42% to $11.11. Over the last five days, the stock has lost -4.31%. EyePoint Pharmaceuticals Inc shares have fallen nearly -51.93% since the year began. Nevertheless, the stocks have risen 73.59% over the past one year. While a 52-week high of $30.99 was reached on 02/08/24, a 52-week low of $5.86 was recorded on 08/14/24. SMA at 50 days reached $9.62, while 200 days put it at $14.21.
Levels Of Support And Resistance For EYPT Stock
The 24-hour chart illustrates a support level at 10.81, which if violated will result in even more drops to 10.51. On the upside, there is a resistance level at 11.69. A further resistance level may holdings at 12.27. The Relative Strength Index (RSI) on the 14-day chart is 52.97, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.17, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 60.46%. Stochastics %K at 49.42% indicates the stock is a holding.
How much short interest is there in EyePoint Pharmaceuticals Inc?
A steep rise in short interest was recorded in EyePoint Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.75 million shares to a total of 9.68 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 8.93 million shares. There was a rise of 7.76%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on April 21, 2023 when Robert W. Baird began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
